Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

Tom Lilly Appreciation Night is another winning night for Cedar Rapids Xavier. Saints get a stern test from Cedar Rapids ...

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...